EP1534317A4 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents

N-terminally truncated galectin-3 and antibodies for treating cancer

Info

Publication number
EP1534317A4
EP1534317A4 EP02756157A EP02756157A EP1534317A4 EP 1534317 A4 EP1534317 A4 EP 1534317A4 EP 02756157 A EP02756157 A EP 02756157A EP 02756157 A EP02756157 A EP 02756157A EP 1534317 A4 EP1534317 A4 EP 1534317A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
treating cancer
terminally truncated
truncated galectin
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02756157A
Other languages
German (de)
French (fr)
Other versions
EP1534317A2 (en
Inventor
Gary A Jarvis
Constance M John
Hakon Leffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MANDALMED Inc
Original Assignee
MANDALMED Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MANDALMED Inc filed Critical MANDALMED Inc
Publication of EP1534317A2 publication Critical patent/EP1534317A2/en
Publication of EP1534317A4 publication Critical patent/EP1534317A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
EP02756157A 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer Withdrawn EP1534317A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29697001P 2001-06-08 2001-06-08
US296970P 2001-06-08
PCT/US2002/018478 WO2002100343A2 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Publications (2)

Publication Number Publication Date
EP1534317A2 EP1534317A2 (en) 2005-06-01
EP1534317A4 true EP1534317A4 (en) 2005-10-12

Family

ID=23144316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02756157A Withdrawn EP1534317A4 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Country Status (4)

Country Link
EP (1) EP1534317A4 (en)
AU (1) AU2002322066A1 (en)
CA (1) CA2488850A1 (en)
WO (1) WO2002100343A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
DE602004014485D1 (en) 2003-04-07 2008-07-31 Prospect Therapeutics Inc COMPOSITION AND APPLICATIONS OF GALECTIN ANTAGONISTS
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
CN102488619B (en) 2011-12-05 2014-08-06 上海交通大学 Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres
EP2934552A4 (en) 2012-12-20 2016-07-27 Ford Henry Health System Method for treating diastolic heart failure by inhibiting galectin-3
WO2015085207A1 (en) * 2013-12-05 2015-06-11 Texas Tech University System Galectin-3 to treat ovarian cancer
EP3102247A4 (en) * 2014-02-03 2017-09-13 Texas Tech University System Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors
CN111700877A (en) 2014-09-03 2020-09-25 吉倪塞思公司 Therapeutic nanoparticles and related compositions, methods and systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006407A1 (en) * 1985-04-23 1986-11-06 Medical Biology Institute IDENTIFICATION OF AN IgE-BINDING PROTEIN BY MOLECULAR CLONING
WO2001068123A2 (en) * 2000-03-13 2001-09-20 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006407A1 (en) * 1985-04-23 1986-11-06 Medical Biology Institute IDENTIFICATION OF AN IgE-BINDING PROTEIN BY MOLECULAR CLONING
WO2001068123A2 (en) * 2000-03-13 2001-09-20 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAZ A ET AL: "Expression of two different endogenous galactoside-binding lectins sharing sequence homology.", CANCER RESEARCH. 1 FEB 1988, vol. 48, no. 3, 1 February 1988 (1988-02-01), pages 645 - 649, XP008051054, ISSN: 0008-5472 *
SANO H ET AL: "Human galectin-3 is a novel chemoattractant for monocytes and macrophages.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 2000, vol. 165, no. 4, 15 August 2000 (2000-08-15), pages 2156 - 2164, XP002341212, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1534317A2 (en) 2005-06-01
CA2488850A1 (en) 2002-12-19
WO2002100343A3 (en) 2005-03-17
WO2002100343A2 (en) 2002-12-19
AU2002322066A1 (en) 2002-12-23

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
EP1383801A4 (en) Antibodies against cancer
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
IL159461A0 (en) Method for enhancing the effectiveness of cancer therapies
EP1476067A4 (en) Novel compositions and methods for cancer
MXPA03008582A (en) Agents and methods for treatment of cancer.
HUP0400775A2 (en) Specific human antibodies for selective cancer therapy
AU2002351374A8 (en) Antibodies to treat cancer
EP1534317A4 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
GB2389532C (en) The method of treating cancer
GB0201498D0 (en) Materials and methods for treating cancer
EP1401377A4 (en) Methods for treating cancer
EP1316560A4 (en) Novel human cancer/testis antigen and gene thereof
EP1469870A4 (en) Novel compositions and methods for cancer
AU2002360815A8 (en) Human breast cancer biomarkers
AU2002305138A1 (en) Methods and materials for cancer treatment
EP1403283A4 (en) Tumor antigen
AU2002366364A8 (en) E2f and cancer therapy
EP1446416A4 (en) Tumor specific monoclonal antibodies
EP1463511A4 (en) Combination cancer therapy
GB2379444A9 (en) Assay for cancer of the prostate
AU2002360454A8 (en) Methods and compositions for treating cancer
SI1157041T1 (en) Antibodies for cancer therapy and diagnosis
GB0104244D0 (en) Marker for antibody therapy
AU2002356097A1 (en) Hydrazinopeptoids and their uses for treating cancers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040105

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050829

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7C 07K 14/47 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07K 16/32 B

Ipc: 7C 07K 14/435 B

Ipc: 7A 61K 39/395 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 38/16 A

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070911

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080122